Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL

• Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006)
• Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence
• In vivo demonstration of ammonia scavenger mechanism of action highlights potential synergistic combination with TLR-4 antagonist (YAQ005)
LONDON, May 7, 2025